ARIAD Reports Positive 12-Month Data from Pivotal PACE Trial of Ponatinib in Heavily Pretreated Chronic-Phase CML Patients
Pharmaceuticals (NASDAQ: ARIA) today announced twelve-month
follow-up data from the pivotal PACE trial of ponatinib,
its investigational BCR-ABL inhibitor, in heavily pretreated patients
with resistant or refractory chronic myeloid leukemia (CML) or
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
The study now shows that 56 percent of chronic-phase CML patients in the
trial, including 70 percent of patients with a T315I mutation, achieved
a major cytogenetic response (MCyR), the primary end-point for
chronic-phase CML patients.
The data are being featured today at 4:30 p.m. (ET) in an oral
presentation at the 54th Annual Meeting of the American Society of
Hematology (ASH) being held in Atlanta,